DGAP-News: SYGNIS AG / Key word(s): Product Launch SYGNIS AG: SYGNIS presents its first own product line based on PrimPol technology: TruePrime(TM) (news with additional features) 20.11.2014 / 08:00 --------------------------------------------------------------------- Press Release SYGNIS presents its first own product line based on PrimPol technology: TruePrime(TM) - TruePrime(TM) revolutionizes whole genome and transcriptome amplification - First product will be developed for single cell DNA amplification - Evaluation by an industry leading partner for use on own Next Generation Sequencing (NGS) platform ongoing - Product launch planned for January 2015 Madrid, Spain and Heidelberg, Germany, November 20th, 2014 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the inaugural launch of its first new product line TruePrime(TM). TruePrime(TM) is the brand name of a series of kits dedicated to the amplification of various DNA or RNA species for a multitude of applications. TruePrime(TM) stands for a revolutionary change in the way DNA or RNA is amplified. While the current gold standard MDA (multiple displacement amplification) needs short pieces of DNA ("oligonucleotides") to start off the amplification, TruePrime(TM) does not need any synthetic random primers. TruePrime(TM) is based on a combination of SYGNIS' recently discovered polymerase TthPrimPol and Phi29 DNA polymerase. In this set up, TthPrimPol synthesizes the primers needed for Phi29 DNA pol on the fly, which allows for the amplification of genomic DNAs. The key advantages of the TruePrime(TM) product line include complete absence of common artifacts linked to the use of oligonucleotides, a reduced amplification bias compared to methods using random synthetic primers and an exquisite reproducibility when DNA is amplified from single mammalian cells. Moreover, TruePrime(TM) shows superior sensitivity, is easy to use and works perfectly well with all commonly used NGS platforms such as Illumina and IonTorrent. The Company plans to launch the first kit for DNA amplification from single cells in January of 2015. Single cell analysis has been named "Method of the year" by the renowned journal "Nature Methods" and today is one of the most exciting but also one of the most challenging applications of NGS. The features of TruePrime(TM) make this product highly attractive for this type of analyses especially in life science areas such as human genetics, oncology, or pathology where researchers need to obtain biological information from the smallest sample amounts. "We are very proud and excited about the development of our first kit from our newly introduced TruePrime(TM) product line. With this product line, based on our proprietary PrimPol technology, we are addressing key challenges in NGS as well as in other downstream applications, where DNA analysis is limited due to small amounts of available sample material down to single cells," Pilar de la Huerta, CEO and CFO of SYGNIS commented. "In addition, we are driving adoption of NGS into more commercial applications by providing solutions which are compatible with major NGS platforms and support standardization of workflows. Given the superiority of TruePrime(TM) over all technologies for whole genome DNA amplification available today, SYGNIS is convinced it will benefit from future growth rates and gain a significant portion of the market." SYGNIS is currently developing a series of TruePrime(TM) kits that are expected to be launched throughout 2015 and 2016 to bring the benefits of this new technology to researchers working on a variety of applications. Starting January 2015, the kits will be available via SYGNIS' own sales channels and through regional and international life science distributors. In addition, SYGNIS is planning to also expand the market for its new products through OEM agreements with international market leading companies. SYGNIS has cloned, characterized, and patented a PrimPol thermostable version, TthPrimPol, following the seminal characterization of human PrimPol by one of SYGNIS' scientific fathers, Prof. Luis Blanco, at the end of 2013. On November 12th, Prof. Blanco was granted with the renowned Carmen and Severo Ochoa Prize 2014 by the Carmen and Severo Ochoa Foundation from the Spanish National Research Council (CSIC), which recognizes the work of excellent scientists in the field of molecular biology in Spain. This brand new amplification technology is patent-protected by SYGNIS until 2033. About PrimPol PrimPol is one of the most innovative discoveries in the molecular biology field and one of the key products in SYGNIS' portfolio. Key features of this enzyme family are the duality as a RNA primase and DNA polymerase, and its high tolerance to damaged DNA. The primase function of PrimPol allows it to start reading and copying DNA without the need for providing primers, as required by all other commercially available polymerases. Using random primers can bias the amplification and sequencing results. The polymerase function of PrimPol displays a highly specific activity, being very efficient also when copying DNA with different lesions. About the Next Generation Sequencing market Today, NGS is seen as the fastest-growing and most lucrative segment in the genomics market with an estimated annual growth rate of more than 23% in the years to come. The global NGS market volume today is worth $2.5 billion and is poised to reach $8.7 billion by 2020 (MarketsandMarkets, September 2014). While still mostly used in research institutions, ongoing developments for higher throughput, increased accuracy, and cost efficiency as well as value creating data management will make NGS more and more attractive for commercial applications such as diagnostics, drug discovery, biomarker discovery as well as personalized medicine in clinical laboratories, hospitals and in pharma companies. For further information please contact: <pre> SYGNIS AG Pilar de la Huerta CEO/CFO Phone: +34 91 192 36 50 Email: pdelahuerta@sygnis.es </pre> About SYGNIS AG: www.sygnis.com Following the merger with X-Pol Biotech in 2012, SYGNIS specializes on the development and commercialization of products for DNA amplification and sequencing. SYGNIS AG, listed at the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), has a commercial product for whole genome DNA amplification, SensiPhi(R), licensed to an industry leading partner and is currently developing its own TruePrime(TM) product line based on its proprietary PrimPol technology for use in the fast growing field of Next Generation Sequencing. The first product for single cell DNA amplification is expected to be launched in January 2015. ### Disclaimer This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.### +++++ Additional features: Document: http://n.equitystory.com/c/fncls.ssp?u=XOSJPHEPOJ Document title: SYGNIS 141120_PR TruePrime_EN --------------------------------------------------------------------- 20.11.2014 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: SYGNIS AG Im Neuenheimer Feld 515 69120 Heidelberg Germany Phone: 06221 454-6 Fax: 06221 454-700 E-mail: contact@sygnis.de Internet: www.sygnis.de ISIN: DE000A1RFM03 WKN: A1RFM0 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 298114 20.11.2014
DGAP-News: SYGNIS AG: SYGNIS presents its first own product
Top 10 Most Recent News Articles
Linkind's Best Buy Push Tests Smart Outdoor Demand
Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...
Continue Reading
Swell Partners' Awards Highlight Culture, Not Metrics
Recognition Lands in a Crowded Talent Market Two shiny Stevie trophies do not pay payroll, but they can say something useful about a company trying to stand out in the noisy talent-services business. Swell Partners has been named 2026 Company of the Year in Business Services and has seen founder and CEO Cari Gatto receive Best Female CEO of the Year. For a private firm...
Continue Reading
Sokin’s UAE License Turns Expansion Into Real Payments Plumbing
Dubai expansion headlines are cheap; regulated local money movement is not. That is why Sokin’s newly approved Dubai Financial Services Authority license deserves more than the usual fintech applause line. The company has paired that approval with AED accounts, local payment rails, a One Za’abeel office and a plan to double its UAE staff over the next year. None of...
Continue Reading
MetaOptics Tests a Real Path Into Secure Imaging Markets
Fingerprint scanners have never impressed me much; fooling one is exactly the sort of nuisance that keeps security buyers spending. MetaOptics’ new collaboration with Hong Kong’s ASTRI goes after that uncomfortable problem with a compact nano-optics imaging system built for biometric security and smart sensing. It is a sensible target. It is also, at this stage, a...
Continue Reading
MetaComp's $10M Extension Tests Stablecoin Rails in Trade
A ten-million-dollar check is cheap until the licensing bills start arriving. MetaComp has added roughly US$10 million from Tether and Abu Dhabi-based Further Asset Management, taking its Pre-A and Pre-A+ fundraising to about US$45 million. The important bit is not the headline-sized pile of cash. It is where management says the money is going: licences, compliance...
Continue Reading
Esquire Spotlight Puts Trauma Cleanup Work in Focus
A national magazine profile is an odd milestone for a business built around other people’s worst days. David Lesaffre, co-owner and operator of T.A.C.T. 48, T.A.C.T. AZ, and T.A.C.T. Fort Worth, has been featured by Esquire in a piece called “The Trauma Cleaners.” The attention is deserved, frankly, because biohazard remediation is one of those necessary services...
Continue Reading
Hagerty's Fifth Film Win Keeps Its Media Engine Humming
A lap record, a camera crew, and five straight trophies make a louder statement than another glossy corporate slogan. Hagerty won Best Journalism Film at the 2026 International Motor Film Awards on Nov. 14, held at the Petersen Automotive Museum in Los Angeles. The company has taken that particular award home five years running, powered again by Jason Cammisa and his...
Continue Reading
Housing's Value Equation Is Getting More Complicated
A homeowner's insurance bill has become a louder market signal than a granite countertop. Green Builder Media's latest batch of research, publishing and events is aimed squarely at that uncomfortable truth: housing is no longer judged only by the price on the contract. Buyers, builders, lenders and insurers are being pushed to reckon with what a home costs to own, protect...
Continue Reading
HiTHIUM's 8-Hour Storage Pitch Faces Real Grid Tests
Eight hours of stored electricity is where the sales brochure meets the ugly parts of the grid. HiTHIUM arrived at RE+ 2026 in Las Vegas, held November 17 through 19, with a broad storage pitch: systems ranging from two to eight hours, lithium-ion and sodium-ion chemistry, plus the software and validation work needed to make a battery plant behave when the local grid gets...
Continue Reading
LevelTen Takes Its Clean-Power Market Model to India
India's power market is not a tidy spreadsheet, thankfully. It is a vast, fast-growing grid where data centres, factories and climate exposure are all colliding with a generation mix still dominated by coal. That is why LevelTen Energy's move into Asia-Pacific deserves more than the usual clean-tech applause line. Beginning with a 500 MW clean-energy request for proposals...
Continue ReadingTop 5 Most Recently Viewed Articles
Private Tutoring Insights: Learning from Finland's Education Method
Exploring Finland's Educational Principles for Private Tutoring In today's rapidly evolving educational landscape, Tutors International passionately investigates various global education models. One system that stands out is Finland's renowned educational approach, widely admired for its emphasis on holistic learning and well-being. Tutors International's latest analysis...
Continue Reading
Charter Communications and Cox Communications Join Forces
Charter Communications Merges with Cox Communications In a pivotal move for the telecommunications industry, Charter Communications and Cox Communications have entered into a definitive agreement to combine their companies. This merger signifies a significant consolidation within the sector, promising advancements in service delivery and enhanced operational efficiency...
Continue Reading
Investor Insights on Dyne Therapeutics: Understanding Risks
Understanding the Current Situation of Dyne Therapeutics Dyne Therapeutics, Inc. (NASDAQ: DYN) is currently under scrutiny as Pomerantz LLP investigates potential claims on behalf of investors. The concerns arise regarding whether Dyne and its executives may have engaged in improper securities practices. Investors holding shares or contemplating an entry into the market...
Continue Reading
Scientology's New Campaign Aims to Inspire Global Engagement
Scientology Launches Global Welcome Campaign The Church of Scientology International is excited to unveil its innovative Global Welcome to Scientology campaign. This initiative is a powerful effort focused on bringing people together and elevating the human experience through understanding and discovery. Inspiring Discovery Across the Globe With the aim of fostering a...
Continue Reading
Deborah R. Willig Shines in Lawdragon's Prestigious Award List
Deborah R. Willig Recognized Among Leading Civil Rights Attorneys Willig, Williams & Davidson proudly announces that Deborah R. Willig, the firm's managing partner, has once again earned a spot in the esteemed Lawdragon 500 list of leading civil rights and plaintiff employment lawyers. This recognition underscores her unwavering commitment to advocating for workers'...
Continue Reading